Loading
Medicare pays for freezing treatment of the prostate as a first treatment for prostate cancer confined to the gland area (stages T1 to T3), and as a second treatment only after radiotherapy has failed and the cancer still meets set limits.
United States, Medicare National Coverage Determination 230.9, version 1, effective 1 July 2001. It states that cryosurgical ablation of the prostate is "safe and effective, as well as medically necessary and appropriate, as primary treatment for patients with clinically localized prostate cancer, Stages T1-T3". Salvage cryosurgery for recurrent cancer is covered only for localised disease in patients who "have failed a trial of radiation therapy as their primary treatment" and meet one of: "Stage T2B or below, Gleason score <9, PSA <8 ng/mL". It is not covered as salvage after failure of other primary treatments, nor for any salvage services before 30 June 2001.
Showing the technology this term belongs to: Cryoablation systems.
Shares Centers for Medicare & Medicaid Services (CMS), PSA (prostate-specific antigen), Prostate cancer and the tag us.
Shares Centers for Medicare & Medicaid Services (CMS) and the tag us.
Shares Centers for Medicare & Medicaid Services (CMS) and the tag us.
Shares Centers for Medicare & Medicaid Services (CMS) and the tag us.
Shares Centers for Medicare & Medicaid Services (CMS) and the tag us.
Shares Centers for Medicare & Medicaid Services (CMS) and the tag us.
Shares Centers for Medicare & Medicaid Services (CMS) and the tag us.
Shares Centers for Medicare & Medicaid Services (CMS) and the tag us.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/